Momenta Pharmaceuticals (NASDAQ:MNTA) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Tuesday.
MNTA has been the subject of several other reports. Stifel Nicolaus reissued a “hold” rating and issued a $18.00 target price on shares of Momenta Pharmaceuticals in a report on Tuesday, January 30th. Zacks Investment Research raised Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, Cowen set a $15.00 target price on Momenta Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $15.30.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at $16.30 on Tuesday. The stock has a market capitalization of $1,250.00, a PE ratio of -20.38 and a beta of 1.80. Momenta Pharmaceuticals has a fifty-two week low of $11.85 and a fifty-two week high of $19.55.
In other news, CEO Craig A. Wheeler sold 10,406 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $15.89, for a total value of $165,351.34. Following the completion of the sale, the chief executive officer now directly owns 275,526 shares of the company’s stock, valued at approximately $4,378,108.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Bruce Leicher sold 1,861 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $16.00, for a total value of $29,776.00. The disclosure for this sale can be found here. Insiders sold a total of 77,354 shares of company stock valued at $1,170,153 over the last three months. Company insiders own 4.40% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of MNTA. Renaissance Technologies LLC raised its stake in Momenta Pharmaceuticals by 186.4% during the 2nd quarter. Renaissance Technologies LLC now owns 797,400 shares of the biotechnology company’s stock valued at $13,476,000 after acquiring an additional 519,000 shares during the last quarter. Vanguard Group Inc. raised its stake in Momenta Pharmaceuticals by 4.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock valued at $105,519,000 after acquiring an additional 290,090 shares during the last quarter. State Street Corp raised its stake in Momenta Pharmaceuticals by 8.1% during the 2nd quarter. State Street Corp now owns 2,653,427 shares of the biotechnology company’s stock valued at $44,842,000 after acquiring an additional 197,978 shares during the last quarter. Fisher Asset Management LLC purchased a new stake in Momenta Pharmaceuticals during the 3rd quarter valued at approximately $1,823,000. Finally, Northern Trust Corp raised its stake in Momenta Pharmaceuticals by 12.1% during the 2nd quarter. Northern Trust Corp now owns 904,238 shares of the biotechnology company’s stock valued at $15,283,000 after acquiring an additional 97,893 shares during the last quarter. 93.01% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Momenta Pharmaceuticals (MNTA) Upgraded to Buy by BidaskClub” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/13/momenta-pharmaceuticals-mnta-upgraded-to-buy-by-bidaskclub.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.